Background. The impact of antibiotic resistance on the clinical outcome of patients with vancomycin-resistant Enterococcus (VRE) bacteremia remains unclear. There are limited data comparing patient outcomes during the early era of vancomycin resistance with the period of more-potent antibiotic availability.
widespread outbreaks in a variety of clinical settings [4] .
Resistant to all standard agents, cases of VRE were initially treated with a variety of drugs that resulted in a variable patient response. Numerous studies debate the significance of vancomycin resistance, some noting a higher crude mortality rate with vancomycin-resistant infection, compared with vancomycin-susceptible infection, and others noting that clinical outcome is primarily dependent on severity of illness and comorbidities [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Thus, the significance of vancomycin resistance as an independent predictor of mortality is still a topic of debate.
Several antibiotics have been introduced more recently that are effective treatment of VRE. The U.S. Food and Drug Administration approved use of quinupristin-dalfopristin (QPD) in 1999. Early studies of QPD related favorable response rates of 75%-88%, with limited adverse reactions [15, 16] . Linezolid (LZD), effective against both Enterococcus faecium and Enterococcus faecalis, was approved in 2000. In a compassionate-use program for subjects with infection due to VRE, LZD was associated with clinical cure in 73% of cases and microbiological cure in 84% of cases [17] . In 2005, daptomycin, a cyclic lipopeptide, was approved for the treatment of skin and soft-tissue infection, including infections due to vancomycin-susceptible enterococci, and also shows activity against VRE [18] . Tigecycline, a glycylcycline with activity against VRE, was brought to market in 2005 [19] . Initial studies and experience are promising, but little data exist comparing any of these newer drugs with each other or with the older, less potent combinations. The impact of antibiotic resistance on the clinical outcome of patients with VRE bacteremia remains unclear. There are few data comparing patient outcome during the early era of vancomycin resistance with outcome during the period of more-potent antibiotic availability. We predicted that morepotent antibiotics would result in improvement in clinical outcome if vancomycin resistance acts as an independent predictor of mortality. To investigate this hypothesis, a retrospective analysis of patients with VRE bacteremia was performed to determine clinical outcome before and after the initiation of morepotent antimicrobial therapy.
METHODS

Patient selection and evaluation. The Nebraska Medical
Center is a 689-bed, tertiary care, academic medical center. The first case of VRE bacteremia at the Nebraska Medical Center occurred in August 1993. A VRE database was prospectively begun at that time and has been maintained by the Infection Control Department and the Clinical Microbiology Laboratory. All cases of VRE bacteremia from August 1993 to September 2005 were included in the initial patient selection for the present study. VRE bacteremia was defined as 11 positive blood culture result, 1 positive blood culture result and isolation of VRE from a normally sterile site, or у1 positive blood culture result and evidence of systemic infection. The records of all patients with VRE bacteremia were further evaluated by a single reviewer (K.M.E.).
The following definitions were used in the evaluation of each patient: VRE colonization was defined as VRE isolated from any site at any time before onset of bacteremia; time to start antibiotics was defined as the time in days between the date the initial blood culture specimen was drawn and the administration of the first dose of antibiotics, grouped into those receiving antibiotics р3 days or 13 days after index blood culture result; other antibiotic treatment (OTH) included any treatment with a tetracycline, ampicillin, chloramphenicol, imipenem-cilastin, rifampin, or an aminoglycoside; degree of renal dysfunction was graded by the log of the serum creatinine; liver dysfunction was defined as an aspartate aminotransferase or alanine aminotransferase level 12 times the upper limit of normal, a bilirubin level 12.5 mg/dL, or a serum albumin level !2.5 g/dL; and steroid use, which included any dose and was distinguished as short term (р30 days) or long term (130 days).
A severity-of-illness score was assigned to each patient as described elsewhere [8, [20] [21] . Scores were calculated by the reviewer with use of a combination of variables with assigned points: mental status (disorientation, 1; change in mental status with stupor, 2; and change in mental status with coma, 4); temperature (137.8Њ, 1; у40Њ, 2; and р35.6Њ, 2); hypotension, 2 (defined as mean arterial pressure !60 or the use of vasopressors); mechanical ventilation, 2; and cardiac arrest, 4. The maximum obtainable score was 14.
Clinical outcomes included a change in mental status, based on clinical evidence of a change recorded in daily progress notes or nursing records; an improvement in mental status, based on clinical evidence of improvement as documented in the daily progress notes or nursing records; and time to defervescence, defined as time to reach a temperature !38.2Њ for 124 h. Other outcome measurements included time to hospital discharge, defined as the time in days from the time of initial identification of bacteremia to the date of discharge, excluding any patients who died; and time to next admission, defined in days, classified as related to VRE infection if the patient was readmitted to the hospital because of a complication of antibiotic therapy for VRE, recurrent bacteremia, or an infection with VRE at another site.
Mortality outcomes were defined as death due to sepsis or multiorgan failure, cardiac dysfunction, malignancy, pulmonary dysfunction, liver dysfunction, or gastrointestinal bleeding, as based on the clinical assumption of the treating physician or pathologist as documented in the progress notes, discharge summary, or autopsy report.
Death directly due to VRE was defined as death occurring in the context of sepsis caused by VRE, with no other obvious cause of death, or indication of VRE as the proximate cause of death on discharge summary, progress notes, or autopsy report. Death indirectly due to VRE was considered if death occurred in the context of polymicrobic bacteremia including VRE, if clinical signs of enterococcal bacteremia had not cleared by the time of death, if clinical decline initially caused by VRE bacteremia led to death, or if VRE was indicated as a contributing factor on the discharge summary, progress notes, or autopsy report. Death unrelated to VRE was defined as death occurring after clinical signs and symptoms, as well as microbiologic data, revealed no evidence of VRE bacteremia, and death was not related to clinical decline precipitated by VRE bacteremia.
Microbiology procedures. All gram-positive cocci isolated from the blood that were pyrrolidonyl peptidase positive (as determined by the PYR [l-pyrrolidonyl-b-naphthylamide] disk) and catalase negative (by testing with 3% hydrogen peroxide) were inoculated to conventional MicroScan Panels (Positive Breakpoint Combo; Dade Berhing) with use of the turbidity standard technique. The panels were incubated a full 24 h at 37ЊC in ambient air and were read using the MicroScan Walkaway-40 System (Remel). Isolates identified as an Enterococcus species with resistance to vancomycin by the MicroScan panel were subsequently subcultured and tested for motility and pigment production. Additionally, the isolate was retested for vancomycin susceptibility with use of the disk-diffusion method. Nonmotile and nonpigmented E. faecalis and E. faecium with resistance to vancomycin were identified as VRE. Antimicrobial susceptibility results were reported for the following agents: ampicillin, chloramphenicol, erythromycin, high-level aminoglycoside, LZD (beginning in 1999), penicillin, QPD (beginning in 1994), rifampin, tetracycline, and vancomycin.
Statistical analysis. For the comparison of demographic characteristics, comorbidities, and clinical outcomes among the 3 groups, the categorical data were analyzed with a x 2 test or Fisher's exact test, and the continuous data were analyzed with the analysis of variance approach, where appropriate; the Kruskall-Wallis test was used otherwise [22] . Multiple comparison was not adjusted unless noted explicitly. Univariate and multiple linear regressions were used for the analysis of the (logtransformed) time interval until hospital discharge [23] . Logistic regression models were used to compare the mortality of the groups after adjustment for severity of illness and comorbidities. Univariate models were fit to select the variables associated with mortality ( ), which were then included in P ! .25 the full model. To select the final model, the full model was started, and the least significant covariates with were P 1 .05 deleted 1 at a time, as long as the estimates and SEs of the group comparisons did not change substantially. All analyses were performed using SAS software, version 9.1 (SAS Institute).
RESULTS
A total of 723 individual patients had VRE detected in clinical specimens during the time period studied. Of these, 157 patients had VRE bacteremia as defined by the study criteria. Forty-four patients were excluded from further analysis for the following reasons: inaccessible medical records or a positive culture obtained before transfer to our institution (35 patients), positive blood culture results only at postmortem (7 patients), or treatment with daptomycin, because there were too few patients for meaningful evaluation (2 patients). The Enterococcus species associated with VRE bacteremia in the remaining 113 patients were E. faecium (112 patients) and E. faecalis (1 patient). All of the isolates were resistant to ampicillin and showed variable resistance to high-level aminoglycosides. LZD resistance was detected in 1 isolate after testing began in October 2002. QPD resistance was detected only in the 1 patient infected with vancomycin-resistant E. faecalis after testing began in July 2000.
The treatment group was determined by the primary team or infectious diseases consultant caring for the patient at the time of onset of VRE bacteremia, and choice of treatment was based on the available antimicrobials, concurrent compassionate-use trials, and patient characteristics. Three patients received LZD and were included in this group for analysis, although treatment was later changed to QPD because LZD resistance was discovered ( a Data are for 11 subjects in the OTH arm, 7 subjects in the QPD arm, and 53 subjects in the LZD arm. b Data are for 14 subjects in the OTH arm, 14 subjects in the QPD arm, and 41 subjects in the LZD arm. c Data are for 8 subjects in the OTH arm, 6 subjects in the QPD arm, and 34 subjects in the LZD arm.
without known prior VRE colonization had a median of 3 days (range, 1-20 days) to initiation of antibiotic treatment, whereas those patients known to be previously colonized with VRE commenced antibiotic treatment in a median of 1.5 days (range, Ϫ5 to 51 days; ). P p .002 The QPD group was treated for a median of 12 days (range, 2-42 days). Complications presumed to be secondary to QPD therapy were observed in 7 patients and included 2 cases (10%) of leukocytosis, 4 cases (20%) of myalgias, and 1 (5%) of lactic acidosis. LZD was given for a median of 14 days (range, 3-70 days) of therapy. Complications occurred in 5 patients, including 1 patient each with lactic acidosis, Clostridium difficile colitis, neuropathy, diarrhea (non-C. difficile), and thrombocytopenia.
Crude and attributable mortality data are summarized in table 2. The mortality rate for all groups was 37% (42 of 113). Sepsis was the leading cause of death (36 of 42) among all groups, with 11 (26%) of 42 deaths directly and 18 (43%) of 42 deaths indirectly attributable to VRE. Univariate analysis indicated significantly fewer deaths in the LZD group compared with the QPD group or the other agent group. After adjustment for severity of illness and other comorbidities, treatment group was not a significant independent factor. Factors associated with mortality were severity-of-illness score (OR, 1.49; 95% CI, 1.13-1.96), renal insufficiency (log of creatinine; OR, 2.45; 95% CI, 1.29-4.63), malignancy (OR, 10.0; 95% CI, 2.95-34.1), prior VRE colonization (OR, 3.03; 95% CI, 1.04-8.87), and underlying liver disease (OR, 6.17; 95% CI, 1.95-19.5). Table 3 summarizes significant risk factors for mortality through univariate analysis and multiple logistical regression. Clinical outcome measurements are summarized in table 4. Because linear regression was used to analyze all groups combined, the APACHE II score, severity-of-illness score, and age were significantly correlated with the (log-transformed) time interval until discharge.
DISCUSSION
The results indicate that, despite more-targeted treatment strategies and specific drugs for VRE, overall mortality may not have been substantially improved. Nearly one-third of the patients died of sepsis, with almost two-thirds of deaths either directly or indirectly associated with VRE. Although patients receiving treatment with LZD seemed to have better outcomes in terms of vasopressor support at 7 days of bacteremia (table  4) as well as crude mortality (table 2), this patient group had significantly fewer transplant recipients, less severe renal dysfunction, and a lower APACHE II score (table 1). The variation in size of treatment group and severity of illness found in the LZD group may, in part, be due to the ease of administration of the drug, as well as the natural evolution of the VRE epidemic. Although the very ill immunocompromised patients were infected with VRE largely in the early years of the epidemic, today's VRE-infected patients range from transplant recipients to relatively stable diabetic patients, nursing home residents, and patients undergoing dialysis. When accounting for differences among the 3 treatment groups, mortality is not substantially improved, despite the use of more-potent antibiotics. This suggests that VRE itself may not be an independent predictor of mortality.
Interestingly, we found that rapidly positive VRE culture results were significantly correlated with death ( ), which P p .01 suggests that shorter time to culture positivity is indicative of high-grade bacteremia and heavy bacterial inoculum. However, the volume of collected blood in our study was not monitored. This may be a potential confounder, as suggested by Mermel and Maki [24] , who noted that the yield of blood cultures increases 3% for every milliliter of blood collected.
With use of the APACHE II score, severity-of-illness score, and other comorbidities in our multivariate analysis, an attempt was made to compare patient populations among the treatment groups. Most studies examining outcomes associated with VRE infection have used the APACHE II score. However, a large portion (38.1%) of our patient population had undergone liver transplantation, and APACHE II in this population has been less useful, unless specific orthotopic liver transplant coefficients are included [25] . Previous VRE studies have used the severity-of-illness score, although no randomized trials have examined the use of this scale in specific patient populations [8, 20, 21] . Looking at both the APACHE II score (without specific coefficients) and the severity-of-illness score, we found that the scores were highly correlated (Pearson correlation, ). In the univariate logistic regression, both APACHE r p 0.68 II (
) and severity-of-illness scores ( ) were sig-P ! .001 P p .008 nificant predictors of death.
When crude mortality is evaluated, several issues need to be considered. Our crude mortality rates (37%) were slightly lower than results of prior studies of VRE bacteremia (range, 33%-79%), which suggests differences in patient characteristics or treatment regimens among study populations [4, 6, 9, [11] [12] [13] . The lower crude mortality may have diminished the presumed benefit of more-potent antibiotics. The QPD group had a slightly later time-to-antibiotic initiation, likely attributable to the compassionate use program in place at that time, requiring more-extensive evaluation and approval. The study is a systematic retrospective review, and unmeasured or unanticipated factors may be present in the pathogen, host, or treatment regimens. Because of incomplete records, some patients were excluded from the study, and because of the possibility of inaccurate medical records, some data may be flawed. Variables such as improvement in mental status, cause of death, and relation of death to VRE were per progress and nursing notes and dependent on the health care worker's opinion at the time, without standardization.
The smaller size of the other agent and QPD groups in our study resulted in less statistical power for comparison. Although randomized controlled studies are needed to further investigate the role of new antibiotics, patient heterogeneity, sample size, and other issues create significant barriers to such studies. A prospective, randomized trial comparing daptomycin and LZD for treatment of VRE infection was recently halted prematurely because of logistical challenges (Barry Eisenstein, Cubist Pharmaceuticals, personal communication). Over a 2-year period, 2470 patients were screened, to enroll 51 subjects (26 who received treatment with daptomycin and 25 who received treatment with LZD). In light of the impediments experienced in this trial, it is not likely that an adequately powered, randomized, controlled trial examining the treatment of infection due to VRE will be conducted.
Unfortunately, with increased use of these newer agents, multiple cases of LZD-, daptomycin-, or QPD-resistant VRE infection have been observed [26] [27] [28] . This emphasizes the need for better means to prevent infection and control the spread of VRE.
In conclusion, despite the development of more-potent antibiotics for treatment of VRE, a significant improvement in outcome was not observed. This suggests that vancomycin resistance is not an independent predictor of mortality. Randomized, controlled trials are needed to further investigate the impact of newer antibiotics, as well as to define improved measures for VRE prevention and control.
